Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.36
+2.7%
$1.23
$0.92
$22.50
$81.00M0.48373,665 shs526,792 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.21
0.0%
$25.17
$11.16
$27.64
$1.07B0.48910,420 shs202,316 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.90
+0.6%
$4.50
$2.19
$26.98
$309.26M0.672.21 million shs1.75 million shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
0.00%+25.46%+2.65%+20.98%-78.42%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-1.17%-10.65%+1.29%+10.19%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.00%+14.47%-5.67%-44.20%-85.49%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.2717 of 5 stars
0.00.00.04.00.00.00.6
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.4129 of 5 stars
3.04.00.04.62.03.30.6
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.4485 of 5 stars
2.22.00.03.92.22.50.6
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
4.8601 of 5 stars
4.22.00.04.71.75.01.3
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50305.90% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4413.96% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.41
Hold$18.60542.27% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RCKT, IGMS, TARO, PCRX, and GBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
6/3/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $11.00
5/30/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line$5.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $9.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$37.00 ➝ $8.00
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M30.22N/AN/A$0.82 per share1.65
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.53$4.31 per share5.38$16.86 per share1.38
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$5.08 per shareN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$3.27N/AN/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A

Latest RCKT, IGMS, TARO, PCRX, and GBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.57N/AN/AN/A$4.36 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/13/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.58-$0.56+$0.02N/AN/AN/A
5/5/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.71
5.71
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.19
9.19
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
CompanyEmployeesShares OutstandingFree FloatOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.70 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240106.79 million80.35 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable

Recent News About These Companies

FDA approves first generics of anticoagulant Xarelto
Taro to acquire 100% stake in Antibe Therapeutics
Sun Pharma unit poised to buy Canadian biotech Antibe

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.36 +0.04 (+2.65%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$1.35 0.00 (-0.37%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.20 -0.01 (-0.02%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$23.88 +0.67 (+2.89%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$2.90 +0.02 (+0.56%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$2.86 -0.04 (-1.42%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.